# A Clinical Study, to Evaluate the Safety and Tolerability of Intradermal IMM-101 in Adult Melanoma Cancer Patients

> **NCT01308762** · PHASE1 · COMPLETED · sponsor: **Immodulon Therapeutics Ltd** · enrollment: 19 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** Heat killed whole cell M. obuense (IMM-101) 0.1 mg
- **BIOLOGICAL:** Heat-killed whole cell M.obuense (IMM-101) 0.5 mg
- **BIOLOGICAL:** Heat killed whole cell M.obuense (IMM-101) 1.0 mg

## Key facts

- **NCT ID:** NCT01308762
- **Lead sponsor:** Immodulon Therapeutics Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2012-12-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01308762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01308762, "A Clinical Study, to Evaluate the Safety and Tolerability of Intradermal IMM-101 in Adult Melanoma Cancer Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01308762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*